Vaccines, medicines and COVID-19 : : how can WHO be given a stronger voice? / / Germán Velásquez.

This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, econ...

Full description

Saved in:
Bibliographic Details
Superior document:SpringerBriefs in Public Health,
VerfasserIn:
Place / Publishing House:Cham : : Springer International Publishing :, Imprint: Springer,, 2022.
Year of Publication:2022
Edition:1st ed. 2022.
Language:English
Series:SpringerBriefs in Public Health,
Physical Description:1 online resource (xvi, 117 pages).
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993544941004498
ctrlnum (CKB)5670000000000228
(NjHacI)995670000000000228
(oapen)https://directory.doabooks.org/handle/20.500.12854/77329
(DE-He213)978-3-030-89125-1
(PPN)259386901
(EXLCZ)995670000000000228
collection bib_alma
record_format marc
spelling Velásquez, Germán , author.
Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? / Germán Velásquez.
1st ed. 2022.
Cham : Springer International Publishing : Imprint: Springer, 2022.
1 online resource (xvi, 117 pages).
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
SpringerBriefs in Public Health, 2192-3701
Includes bibliographical references and index.
English
This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate — particularly in relation to drugs and vaccines — that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.
Chapter 1: COVID-19 Vaccines: Between Ethics, Health and Economics -- Chapter 2: Medicines and Intellectual Property: 10 Years of the WHO Global Strategy -- Chapter 3: Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 -- Chapter 4: Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock -- Chapter 5: Intellectual Property and Access to Medicines and Vaccines -- Chapter 6: The World Health Organization Reforms in the Time of COVID-19 -- Epilogue.
Open Access
COVID-19 (Disease) Political aspects.
COVID-19 (Disease) Social aspects.
COVID-19 Pandemic, 2020-
3-030-89124-0
language English
format eBook
author Velásquez, Germán ,
spellingShingle Velásquez, Germán ,
Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? /
SpringerBriefs in Public Health,
Chapter 1: COVID-19 Vaccines: Between Ethics, Health and Economics -- Chapter 2: Medicines and Intellectual Property: 10 Years of the WHO Global Strategy -- Chapter 3: Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 -- Chapter 4: Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock -- Chapter 5: Intellectual Property and Access to Medicines and Vaccines -- Chapter 6: The World Health Organization Reforms in the Time of COVID-19 -- Epilogue.
author_facet Velásquez, Germán ,
author_variant g v gv
author_role VerfasserIn
author_sort Velásquez, Germán ,
title Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? /
title_sub how can WHO be given a stronger voice? /
title_full Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? / Germán Velásquez.
title_fullStr Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? / Germán Velásquez.
title_full_unstemmed Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? / Germán Velásquez.
title_auth Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? /
title_new Vaccines, medicines and COVID-19 :
title_sort vaccines, medicines and covid-19 : how can who be given a stronger voice? /
series SpringerBriefs in Public Health,
series2 SpringerBriefs in Public Health,
publisher Springer International Publishing : Imprint: Springer,
publishDate 2022
physical 1 online resource (xvi, 117 pages).
edition 1st ed. 2022.
contents Chapter 1: COVID-19 Vaccines: Between Ethics, Health and Economics -- Chapter 2: Medicines and Intellectual Property: 10 Years of the WHO Global Strategy -- Chapter 3: Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 -- Chapter 4: Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock -- Chapter 5: Intellectual Property and Access to Medicines and Vaccines -- Chapter 6: The World Health Organization Reforms in the Time of COVID-19 -- Epilogue.
isbn 3-030-89125-9
3-030-89124-0
issn 2192-3701
callnumber-first R - Medicine
callnumber-subject RA - Public Medicine
callnumber-label RA644
callnumber-sort RA 3644 C67 V453 42022
illustrated Not Illustrated
dewey-hundreds 300 - Social sciences
dewey-tens 360 - Social problems & social services
dewey-ones 362 - Social welfare problems & services
dewey-full 362.1962414
dewey-sort 3362.1962414
dewey-raw 362.1962414
dewey-search 362.1962414
work_keys_str_mv AT velasquezgerman vaccinesmedicinesandcovid19howcanwhobegivenastrongervoice
status_str c
ids_txt_mv (CKB)5670000000000228
(NjHacI)995670000000000228
(oapen)https://directory.doabooks.org/handle/20.500.12854/77329
(DE-He213)978-3-030-89125-1
(PPN)259386901
(EXLCZ)995670000000000228
carrierType_str_mv cr
hierarchy_parent_title SpringerBriefs in Public Health,
is_hierarchy_title Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? /
container_title SpringerBriefs in Public Health,
_version_ 1787548474263207936
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04208cam a22004935i 4500</leader><controlfield tag="001">993544941004498</controlfield><controlfield tag="005">20231122201520.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr#|||||||||||</controlfield><controlfield tag="008">211224s2022 sz o 001 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-030-89125-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-030-89125-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5670000000000228</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995670000000000228</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/77329</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)978-3-030-89125-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PPN)259386901</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995670000000000228</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RA644.C67</subfield><subfield code="b">.V453 2022</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MBN</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED076000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MBN</subfield><subfield code="2">thema</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">362.1962414</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Velásquez, Germán ,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Vaccines, medicines and COVID-19 :</subfield><subfield code="b">how can WHO be given a stronger voice? /</subfield><subfield code="c">Germán Velásquez.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2022.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham :</subfield><subfield code="b">Springer International Publishing :</subfield><subfield code="b">Imprint: Springer,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xvi, 117 pages).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">SpringerBriefs in Public Health,</subfield><subfield code="x">2192-3701</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate — particularly in relation to drugs and vaccines — that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&amp;D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Chapter 1: COVID-19 Vaccines: Between Ethics, Health and Economics -- Chapter 2: Medicines and Intellectual Property: 10 Years of the WHO Global Strategy -- Chapter 3: Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 -- Chapter 4: Rethinking R&amp;D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock -- Chapter 5: Intellectual Property and Access to Medicines and Vaccines -- Chapter 6: The World Health Organization Reforms in the Time of COVID-19 -- Epilogue.</subfield></datafield><datafield tag="506" ind1="0" ind2=" "><subfield code="a">Open Access</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">COVID-19 (Disease)</subfield><subfield code="x">Political aspects.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">COVID-19 (Disease)</subfield><subfield code="x">Social aspects.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">COVID-19 Pandemic, 2020-</subfield></datafield><datafield tag="776" ind1="0" ind2=" "><subfield code="z">3-030-89124-0</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">SpringerBriefs in Public Health,</subfield><subfield code="x">2192-3701</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-11-23 19:59:21 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-01-08 21:49:58 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337794860004498&amp;Force_direct=true</subfield><subfield code="Z">5337794860004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337794860004498</subfield></datafield></record></collection>